Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Brand Name :
Tenex, Intuniv
Synonyms :
guanfacine
Class :
Alpha2-Adrenergic Agonist; Antihypertensive agents
Dosage forms & Strengths:Â
Adult:Â
TabletÂ
1 mgÂ
2 mgÂ
Dosage forms & Strengths:Â
TabletÂ
1 mgÂ
2 mgÂ
Extended-release tabletÂ
1 mgÂ
2 mgÂ
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
may have an increased AV-blocking effect when combined with beta-blockers
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with guanfacine
may diminish the concentration of serum when combined with guanfacine
may diminish the concentration of serum when combined with guanfacine
beta
beta
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
may decrease the antihypertensive effect when combined with alpha2-agonists
may increase the vasoconstricting effect of Ergot Derivatives
esketamine: they may increase the hypertensive effect of Alpha2-Agonists
linezolid: they may increase the hypertensive effect of Alpha2-Agonists
CYP3A strong enhancers of the small intestine may reduce the bioavailability of guanfacine
may increase the hypertensive effect
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
mianserin: it may decrease the therapeutic effect of Alpha2-Agonists
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
fedratinib increases the effect of guanfacine by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the therapeutic effect when combined with Alpha-/Beta-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
zavegepant: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
doxofylline: they may increase the hypertensive effect of Alpha2-Agonists
fentanyl: they may increase the hypertensive effect of Alpha2-Agonists
tedizolid: they may increase the hypertensive effect of Alpha2-Agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
acetaminophen/dextromethorphan/pseudoephedrine/guaifenesin
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
brompheniramine, dextromethorphan and phenylephrine
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
decongestant: they may increase the hypertensive effect of Alpha 2-Agonists
sympathomimetics: they may increase the hypertensive effect of Alpha 2-Agonists
sympathomimetics: they may increase the hypertensive effect of Alpha 2-Agonists
sympathomimetics: they may increase the hypertensive effect of Alpha 2-Agonists
sympathomimetics: they may increase the hypertensive effect of Alpha 2-Agonists
sympathomimetics: they may increase the hypertensive effect of Alpha 2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
>10%:Â
Xerostomia Â
Somnolence Â
Headache Â
Dizziness Â
Constipation Â
Fatigue Â
Abdominal pain Â
1-10%:Â
Hypotension Â
Asthenia Â
Impotence Â
Lethargy Â
Dizziness Â
Irritability Â
Nausea Â
Decreased appetite Â
Weakness Â
Insomnia Â
Bradycardia Â
Palpitations Â
Confusion Â
Depression Â
Dyspnea Â
Alopecia Â
Dermatitis Â
Diaphoresis Â
Pruritus Â
Dyspepsia Â
Dysphagia Â
Hypokinesia Â
Leg crampsÂ
Frequency undefined:Â
RashÂ
ExfoliationÂ
ArthralgiaÂ
MyalgiaÂ
Orthostatic hypotension
Guanfacine is contraindicated in patients hypersensitive to the active ingredient.Â
Pregnancy consideration:Â Â
Guanfacine is not identified with any drug-related side effects in pregnant women.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of the drug in breast milk.Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: guanfacineÂ
Pronounced: gu-aan-fa-cinÂ
Why do we use guanfacine?Â
Guanfacine is an alpha2 adrenergic agonist. It is used to treat hypertension and ADHD in children.  Â